Related Experiment Video
Updated: Jun 11, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Modulation of P-gp expression by lapatinib
Gráinne Dunne1, Laura Breen, Denis M Collins
1National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Abstract:
Chemotherapy drug resistance is a major obstacle in the treatment of cancer. It can result from an increase in levels of cellular drug efflux pumps, such as P-glycoprotein (P-gp). Lapatinib, a growth factor receptor tyrosine kinase inhibitor, is currently in clinical trials for treatment of breast cancer. We examined the impact of co-incubation of chemotherapy drugs in combination with lapatinib in P-gp over-expressing drug resistant cells. Unexpectedly, lapatinib treatment, at clinically relevant concentrations, increased levels of the P-gp drug transporter in a dose- and time-responsive manner. Conversely, exposure to the epidermal growth factor (EGF), an endogenous growth factor receptor ligand, resulted in a decrease in P-gp expression. Despite the lapatinib-induced alteration in P-gp expression, use of accumulation, efflux and toxicity assays demonstrated that the induced alteration in P-gp expression by lapatinib had little direct impact on drug resistance.
Insights
Lapatinib, used in breast cancer treatment, unexpectedly increased P-glycoprotein (P-gp) drug transporter levels in resistant cells. However, this did not significantly impact chemotherapy drug resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chemotherapy drug resistance is a significant challenge in cancer therapy.
- Increased expression of drug efflux pumps, like P-glycoprotein (P-gp), contributes to this resistance.
- Lapatinib is an investigational tyrosine kinase inhibitor for breast cancer.
Purpose of the Study:
- To investigate the effect of lapatinib on P-gp expression in drug-resistant cancer cells.
- To determine if lapatinib affects chemotherapy drug resistance in P-gp over-expressing cells.
Main Methods:
- Co-incubation of P-gp over-expressing cells with chemotherapy drugs and lapatinib.
- Dose- and time-response studies of lapatinib on P-gp levels.
- Accumulation, efflux, and toxicity assays to assess drug resistance.
- Comparison with the effect of epidermal growth factor (EGF) on P-gp.
Main Results:
- Lapatinib treatment increased P-gp transporter levels in a dose- and time-dependent manner.
- Epidermal growth factor (EGF) exposure decreased P-gp expression.
- Despite increased P-gp levels, lapatinib showed minimal direct impact on overall drug resistance.
Conclusions:
- Lapatinib can upregulate P-gp expression in resistant cancer cells.
- This lapatinib-induced increase in P-gp does not significantly alter chemotherapy drug resistance.
- Further research is needed to understand the complex interactions between lapatinib and drug efflux pumps.
Related Concept Videos
Abnormal Proliferation
GPCRs Regulate Adenylyl Cylase Activity
Two...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
